Rigel Pharmaceuticals Inc financial data

Symbol
RIGL on Nasdaq
Location
611 Gateway Boulevard, Suite 900, South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 4, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 216 % +31.7%
Quick Ratio 11.1 % +6.14%
Debt-to-equity 256 %
Return On Equity 205 %
Return On Assets 57.4 % +1792%
Operating Margin 42.2 % +599%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 18.2M shares +3.05%
Common Stock, Shares, Outstanding 17.7M shares +1.3%
Entity Public Float 143M USD -35.7%
Common Stock, Value, Issued 18K USD +5.88%
Weighted Average Number of Shares Outstanding, Basic 18M shares +2.49%
Weighted Average Number of Shares Outstanding, Diluted 19.2M shares +8.55%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 282M USD +79.1%
Costs and Expenses 163M USD +10.2%
Operating Income (Loss) 119M USD +1152%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 114M USD +122%
Income Tax Expense (Benefit) 1.04M USD
Net Income (Loss) Attributable to Parent 113M USD +2819%
Earnings Per Share, Basic 6 USD/shares +118%
Earnings Per Share, Diluted 6 USD/shares +109%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 48.5M USD -6.11%
Cash, Cash Equivalents, and Short-term Investments 137M USD +124%
Accounts Receivable, after Allowance for Credit Loss, Current 45.9M USD +50.2%
Inventory, Net 13.3M USD +178%
Other Assets, Current 5.86M USD
Assets, Current 215M USD +102%
Property, Plant and Equipment, Net 54K USD -45.5%
Operating Lease, Right-of-Use Asset 1.05M USD +159%
Other Assets, Noncurrent 1.17M USD -75.5%
Assets 243M USD +74%
Accounts Payable, Current 3.85M USD +0.81%
Employee-related Liabilities, Current 10.1M USD +27%
Contract with Customer, Liability, Current 1.36M USD 0%
Liabilities, Current 94.4M USD +73.8%
Operating Lease, Liability, Noncurrent 556K USD
Other Liabilities, Noncurrent 40M USD 0%
Liabilities 125M USD -18.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 96K USD +773%
Retained Earnings (Accumulated Deficit) -1.29B USD +8.07%
Stockholders' Equity Attributable to Parent 118M USD
Liabilities and Equity 243M USD +74%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -893K USD +82.2%
Net Cash Provided by (Used in) Financing Activities 484K USD
Net Cash Provided by (Used in) Investing Activities -10.6M USD -3471%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 17.7M shares +1.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 48.6M USD -6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.65M USD -1.84%
Deferred Tax Assets, Valuation Allowance 329M USD -2.78%
Deferred Tax Assets, Gross 329M USD -2.78%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 113M USD +2802%
Lessee, Operating Lease, Liability, to be Paid 1.27M USD +160%
Property, Plant and Equipment, Gross 353K USD -81.1%
Operating Lease, Liability, Current 594K USD +27.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 409K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 692K USD +130%
Deferred Tax Assets, Operating Loss Carryforwards 223M USD -3.14%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 8.78M USD +1.25%
Operating Lease, Payments 16K USD -97.9%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 2.3M USD +27.8%
Depreciation, Depletion and Amortization 604K USD +51%
Share-based Payment Arrangement, Expense 12.1M USD -1.54%
Interest Expense 7.58M USD -3.74%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%